LivaNova (LIVN) Cash from Financing Activities (2015 - 2026)
LivaNova (LIVN) reported Cash from Financing Activities of -$94.2 million for Q1 2026, down 2031.76% on a YoY basis from $4.9 million in Q1 2025, and down 49.87% sequentially from -$62.9 million in Q4 2025.
LivaNova (LIVN) Cash from Financing Activities (2015 - 2026) Analysis & Trends
LivaNova (LIVN) has 12 years of Cash from Financing Activities data on file, last reported at -$94.2 million in Q1 2026.
- For the quarter ending Q1 2026, Cash from Financing Activities fell 2031.76% year-over-year to -$94.2 million; the trailing twelve-month figure through Mar 2026 stood at -$375.5 million (down 1531.33% YoY), and the FY2025 full-year result was -$285.7 million, down 1639.86% from the prior year.
- Cash from Financing Activities eased to -$94.2 million in Q1 2026, from -$62.9 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $214.9 million in Q1 2022 to a low of -$209.0 million in Q2 2025.
- A 5-year average of -$3.5 million and a median of -$4.4 million in 2025 frame the typical range for Cash from Financing Activities.
- Across the five-year window, Cash from Financing Activities surged 2680.18% in 2022 and plunged 2031.76% in 2026, its largest moves.
- Tracing LIVN's Cash from Financing Activities over 5 years: stood at -$1.7 million in 2022, then tumbled by 202.84% to -$5.0 million in 2023, then jumped by 31.37% to -$3.4 million in 2024, then slumped by 1725.9% to -$62.9 million in 2025, then sank by 49.87% to -$94.2 million in 2026.
- Business Quant data shows LIVN's Cash from Financing Activities at -$94.2 million in Q1 2026, -$62.9 million in Q4 2025, and -$9.4 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 17.31 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | -1.51 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | -888.00 Mn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | -260.00 Mn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | -451.20 Mn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | -25.00 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | -26.93 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 21.00 Mn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | LivaNova | 4.30 Bn | 3.76 Bn | 243.75 Mn | -94.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -94.25 Mn |
| Mar 31, 2026 | -94.25 Mn |
| Dec 31, 2025 | -62.88 Mn |
| Dec 31, 2025 | -62.88 Mn |
| Sep 30, 2025 | -9.37 Mn |
| Sep 30, 2025 | -9.37 Mn |
| Jun 30, 2025 | -208.98 Mn |
| Jun 30, 2025 | -208.98 Mn |
| Mar 31, 2025 | -4.42 Mn |
| Mar 31, 2025 | -4.42 Mn |
| Dec 31, 2024 | -3.44 Mn |
| Dec 31, 2024 | -3.44 Mn |
| Sep 30, 2024 | -3.28 Mn |
| Sep 30, 2024 | -3.28 Mn |
| Jun 30, 2024 | -11.87 Mn |
| Jun 30, 2024 | -11.87 Mn |
| Mar 31, 2024 | 37.15 Mn |
| Mar 31, 2024 | 37.15 Mn |
| Dec 31, 2023 | -5.02 Mn |
| Dec 31, 2023 | -5.02 Mn |